WilmerHale Advises Repare Therapeutics, Inc. in Global Research Collaboration With Bristol Myers Squibb

Download IconDownload Print IconPrint

WilmerHale Advises Repare Therapeutics, Inc. in Global Research Collaboration With Bristol Myers Squibb

Client News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
We leverage technical knowledge, business acumen and legal experience to structure, prepare and negotiate innovative and effective technology-related agreements.

On May 26, 2020, Repare Therapeutics Inc., a precision oncology company, announced it had entered an exclusive, worldwide research collaboration with Bristol Myers Squibb. Under the terms of the agreement, the companies will leverage Repare’s proprietary, CRISPR-enabled genome-wide synthetic lethal target discovery program, SNIPRx®, to jointly identify multiple synthetic lethal precision oncology targets for drug candidates. Additionally, Repare will grant BMS exclusive worldwide rights to develop and commercialize therapeutics for select validated lethal precision oncology targets discovered under the collaboration.

BMS will make an upfront payment of $65 million, which includes a $15 million equity investment in Repare. Repare will be eligible to receive up to approximately $3 billion in license fees and discovery, development, regulatory and sales-based milestones, in addition to royalty payments on net sales of each product commercialized by BMS.

The WilmerHale team representing Repare was led by Partner Steve Barrett, and included Counsel Jenna Ventorino and Senior Associate Mat Trachok.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel